Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet ...
During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what ...
Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback